$ACB

AURORA CANNABIS INC

Aurora Cannabis produces, distributes and sells medical cannabis products in Canada and international markets, with very limited activity in Canada’s consumer cannabis market. Its principal medical markets include Canada, Germany, the UK, Poland and Australia. Products include dried flower, pre-rolls, oils, concentrates, vapes, gummies and other formats. Aurora also develops cannabis genetics and cultivars, and licenses its genetics to other Canadian producers. Through its wholly owned subsidiary CanvasRx and other cannabis clinics, it provides patient counseling and outreach. Aurora sells medical cannabis directly to registered patients in Canada through its online shop and client care center, and distributes products internationally under applicable regulations, including through exports and local distribution networks. Its activities also include wholesale production and distribution in the European Union and wholesale distribution in markets such as Australia, New Zealand and the Caribbean. Aurora is headquartered in Edmonton, Alberta, Canada.

2
1
0

No SEC Form 4 filings for $ACB in the last 30 days.

See all $ACB insider activity →
Low

Cannabis Stocks Today 16 Nov 2026: Aurora sits at $4.94

Cannabis stocks mostly declined, with 24 of 35 tracked tickers falling. Aurora Cannabis (ACB) dropped 1.00% to $4.94, below takeover offers from Organigram (OGI) and Curaleaf (CURLF). MSOS ETF fell 3.63% to $3.72. Curaleaf reported Q3 revenue of $353M, up 11%. Glass House (GLASF) and Vext Science (VEXTF) saw steep declines.

Organigram Announces Agreement to Acquire Aurora Cannabis

Organigram (TSE:OGI) agreed to acquire Aurora Cannabis for approximately C$561 million. Organigram secured C$210 million in credit facilities and a £99.9 million investment from BAT. Analysts have mixed views on OGI, with a Buy rating and C$3.00 target, while TipRanks' AI rates it Neutral.

Curaleaf Holdings, Inc. Investor Relations Curaleaf Receives All Required Competition Law Clearances for Proposed Acquisition of Aurora Cannabis

Curaleaf Holdings, Inc. (CURLF) filed an SEC Form 8-K — Other Events. Curaleaf Holdings, Inc. Investor Relations Curaleaf Receives All Required Competition Law Clearances for Proposed Acquisition of Aurora Cannabis STAMFORD, Conn., Nov. 10, 2026 /PRNewswire/ -- Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) (the "Company"), a leading internatio

ACB sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 3 news stories mentioning ACB (AURORA CANNABIS INC). Coverage has skewed bullish: 2 bullish, 1 neutral, and 0 bearish.

Recent ACB coverage spans mergers & acquisitions, market movers and corporate actions.

What's driving ACB

AlphAI scores every news story that mentions ACB with an AI model for sentiment and relevance, and aggregates insider trades from AURORA CANNABIS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $ACB

Score

Cannabis Stocks Today 16 Nov 2026: Aurora sits at $4.94

Cannabis stocks mostly declined, with 24 of 35 tracked tickers falling. Aurora Cannabis (ACB) dropped 1.00% to $4.94, below takeover offers from Organigram (OGI) and Curaleaf (CURLF). MSOS ETF fell 3.63% to $3.72. Curaleaf reported Q3 revenue of $353M, up 11%. Glass House (GLASF) and Vext Science (VEXTF) saw steep declines.

$CURLFHighAI 8/10M&A· acquirer · announced

Curaleaf Holdings, Inc. Investor Relations Curaleaf Receives All Required Competition Law Clearances for Proposed Acquisition of Aurora Cannabis

Curaleaf Holdings, Inc. (CURLF) filed an SEC Form 8-K — Other Events. Curaleaf Holdings, Inc. Investor Relations Curaleaf Receives All Required Competition Law Clearances for Proposed Acquisition of Aurora Cannabis STAMFORD, Conn., Nov. 10, 2026 /PRNewswire/ -- Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) (the "Company"), a leading internatio

$ACBHighAI 9/10

Aurora Cannabis Record International Medical Revenue – Quarterly Update Report

Aurora Cannabis (ACB) reported record international medical revenue of C$61.4M, up 44% y/y, driving 2Q FY27 revenue to C$86.0M. Adjusted EBITDA improved to C$14.0M. ACB agreed to be acquired by Organigram for C$7.80/share, a 93% premium, valuing it at C$561M. ACB shareholders will retain ~35% ownership. The deal aims to create a global cannabis leader with expanded international reach and manufacturing scale.

Related tickers